Heat shock protein 90: The cancer chaperone

Journal of Biosciences

Volumn 32, Issue 3, 2007, Pages 517-530

  Neckers, Len ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Hsp90; Huntingtin; Molecular chaperone; Neurodegeneration; Protein folding

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 AMINOGELDANAMYCIN; 17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANAPLASTIC LYMPHOMA KINASE; ANGIOGENESIS INHIBITOR; ANSAMYCIN DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC ANTIBIOTIC; BCR ABL PROTEIN; BORTEZOMIB; CD135 ANTIGEN; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; NUCLEOPHOSMIN; PROTEASOME INHIBITOR; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RADICICOL; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VORINOSTAT;

CANCER; DRUG; GENE EXPRESSION; INHIBITOR; PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL; CANCER GROWTH; CELL SURFACE; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENDOPLASMIC RETICULUM; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAST CELL LEUKEMIA; MASTOCYTOSIS; MELANOMA; MONOTHERAPY; NAUSEA; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TESTIS CANCER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS;

EID: 34248187981     PISSN: 02505991     EISSN: 02505991     Source Type: Journal    
DOI: 10.1007/s12038-007-0051-y     Document Type: Article

References (122)

1. Aghajanian C, Soignet S, Dizon D S, Pien C S, Adams J, Elliott P J, Sabbatini P, Miller V, Hensley M L, Pezzulli S, Canales C, Daud A and Spriggs D R 2002 A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies; Clin. Cancer Res. 8 2505-2511
2. Agrawal N, Pallos J, Slepko N, Apostol B L, Bodai L, Chang L-W, Chiang A-S, Thompson L M and Marsh J L 2005 Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila; Proc. Natl. Acad. Sci. USA 102 3777-3781
3. Ali A, Bharadwaj S, O'Carroll R and Ovsenek N 1998 HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes; Mol. Cell. Biol. 18 4949-4960
4. An, W G, Schulte, T W and Neckers, L M 2000 The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome; Cell Growth Differ. 11 355-360
5. Auluck P K and Bonini, N M 2002b Pharmacological prevention of Parkinson disease in Drosophila; Nat. Med. 8 1185-1186
6. Auluck P K, Chan H Y, Trojanowski J Q, Lee V M -Y and Bonini N M 2002a Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease; Science 295 865-868
7. Bagatell R and Whitesell L 2004 Altered Hsp90 function in cancer: a unique therapeutic opportunity; Mol. Cancer Ther. 3 1021-1030
8. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang H G, Richon V and Bhalla K 2005 Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2; Clin. Cancer Res. 11 6382-6389
9. Banerji U, O'Donnell A, Scurr M, Benson C, Hanwell J, Clark S, Raynaud F, Turner A, Walton M, Workman P and Judson I 2001 Phase I Trial of the Heat Shock Protein 90 (HSP90) Inhibitor 17-Allylamino 17-Demethoxygeldanamycin 17aag). Pharmacokinetic (PK) Profile and Pharmacodynamic (PD) Endpoints; Proc. Am. Soc. Clin. Oncol. 20 abstract 326
10. Banerji U, O'Donnell A, Scurr M, Benson C, Stapleton S, Raynaud F, Clarke S, Turner A, Workman P and Judson I 2003 A pharmacokinetically (PK) - pharmacodynamically (PD) guided phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG); Proc. Am. Soc. Clin. Oncol. 22 abstract 797
11. Banerji U, O'donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P and Judson I 2005 Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino,17-demethoxygeldanamycin in patients with advanced malignancies; J. Clin. Oncol. 23 4152-4161
12. Banerji U, O'Donnell A, Scurr M, Benson C, Brock C, Hanwell J, Stapleton S, Raynaud F, Simmons L, Turner A, Walton M, Workman P and Judson I 2002 A pharmacokinetically (Pk) - pharmacodynamically (Pd) driven phase I trial of the Hsp90 molecular chaperone inhibitor 17-allyamino 17-demethoxygeldanamycin (17AAG); Proc. 93rd Annu. Meet Am. Assoc. Cancer Res. 43 Abstract 1352
13. Basso A D, Solit D B, Chiosis G, Giri B, Tsichlis P and Rosen N 2002 Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function; J. Biol. Chem. 277 39858-39866
14. Becker B, Multhoff G, Farkas B, Wild P J, Landthaler M, Stolz W and Vogt T 2004 Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases; Exp. Dermatol. 13 27-32
15. Belinsky M and Jaiswal A K 1993 NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues; Cancer Metastasis Rev. 12 103-117
16. Bisht K S, Bradbury C M, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz K L, Sieck L K, Isaacs J S, Brechbiel M W, Mitchell J B, Neckers L M and Gius D 2003 Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signalling and cytotoxicity; Cancer Res. 63 8984-8995
17. Bonvini P, Gastaldi T, Falini B and Rosolen A 2002 Nucleophosminanaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17- demethoxygeldanamycin; Cancer Res. 62 1559-1566
18. Bottaro D P and Liotta L A 2003 Out of air is not out of action; Nature (London) 423 593-595
19. Burger A M, Fiebig H H, Newman D J, Camalier R F and Sausville E A 1998 Antitumor activity of 17-allylaminogeldanamycin (NSC 330507) in melanoma xenografts is associated with decline in Hsp90 protein expression; 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, abstract 504
20. Burger A M, Sausville E A, Carmalier R F, Newman D J and Fiebig H H 2000 Response of human melanomas to 17-AAG is associated with modulation of the molecular chaperone function of Hsp90; Proc. Am. Assoc. Cancer Res. 41 abstract 2844
21. Cheung K M, Matthews T P, James K Rowlands M G, Boxall K J, Sharp S Y, Maloney A, Roe S M, Prodromou C, Pearl L H, Aherne G W, McDonald E and Workman P 2005 The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors; Bioorg. Med. Chem. Lett. 15 3338-3343
22. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L and Neckers L 2003 17AAG: Low Target Binding Affinity and Potent Cell Activity-Finding an Explanation; Mol. Cancer Ther. 2 123-129
23. Chiosis G, Lucas B, Huezo H, Solit D, Basso A and Rosen N 2003 Development of purine-scaffold small molecule inhibitors of Hsp90; Curr. Cancer Drug Targets 3 371-376
24. Chiosis G, Lucas B, Shtil A, Huezo H and Rosen N 2002 Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase; Bioorg. Med. Chem. 10 3555-3564
25. Chiosis G, Vilenchik M, Kim J and Solit D 2004 Hsp90: the vulnerable chaperone; Drug Discov. Today 9 881-888
26. Cohen F E 1999 Protein misfolding and prion diseases; J. Mol. Biol. 293 313-320
27. Cohen M S, Hussain H B and Moley J F 2002 Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors; Surgery 132 960-966; discussion 966-967
28. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P and Marais R 2005 Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin; Cancer Res. 65 10686-10691
29. DeBoer C, Meulman P A, Wnuk R J and Peterson D H 1970 Geldanamycin, a new antibiotic; J. Antibiot. (Tokyo) 23 442-447
30. Dias S, Shmelkov S V, Lam G and Rafii S 2002 VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition; Blood 99 2532-2540
31. Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, Zimmermann J and Lydon N B 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells; Nat. Med. 2 561-566
32. Dymock B W, Barril X, Brough P A, Cansfield J E, Massey A, McDonald E, Hubbard R E, Surgenor A, Roughley S D, Webb P, Workman P, Wright L and Drysdale M J 2005 Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design; J. Med. Chem. 48 4212-4215
33. Egorin M J, Lagattuta T F, Hamburger D R, Covey J M, White K D, Musser S M and Eiseman J L 2002 Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats; Cancer Chemother. Pharmacol. 49 7-19
34. Egorin M J, Rosen D M, Wolff J H, Callery P S, Musser S M and Eiseman J L 1998 Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations; Cancer Res. 58 2385-2396
35. Eiseman J L, Lan J, Lagattuta T F, Hamburger D R, Joseph E, Covey J M and Egorin M J 2005 Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino) ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts; Cancer Chemother. Pharmacol. 55 21-32
36. Eustace B K and Jay D G 2004 Extracellular Roles for the Molecular Chaperone, hsp90; Cell Cycle 3 1098-1100
37. Eustace B K, Sakurai T, Stewart J K, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning S W, Beste G, Scroggins B T, Neckers L, Ilag L L and Jay D G 2004 Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness; Nat. Cell Biol. 6 507-514
38. Feany M B and Bender W W 2000 A Drosophila model of Parkinson's disease; Nature (London) 404 394-398
39. French B A, van Leeuwen F, Riley N E, Yuan Q X, Bardag-Gorce F, Gaal K, Lue Y H, Marceau N and French S W 2001 Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin; Exp. Mol. Pathol. 71 241-246
40. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S and Yamamoto T 1996 Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5); Proc. Natl. Acad. Sci. USA 93 4181-4186
41. Fumo G, Akin C, Metcalfe D D and Neckers L 2004 17-Allylamino-17- demethoxygeldanamycin (17-AAG) is effective in downregulating mutated, constitutively activated KIT protein in human mast cells; Blood 103 1078-1084
42. Georget V, Terouanne B, Nicolas, J -C and Sultan C 2002 Mechanism of antiandrogen action: Key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor; Biochemistry 41 11824-11831
43. Giffard R G, Xu L, Zhao H, Carrico W, Ouyang Y B, Qiao Y, Sapolsky R, Steinberg G, Hu B and Yenari M A 2004 Chaperones, protein aggregation, and brain protection from hypoxic/ischemic injury; J. Exp. Biol. 207 3213-3220
44. Goetz M P, Toft D O, Ames M M and Erlichman C 2003 The Hsp90 chaperone complex as a novel target for cancer therapy; Ann. Oncol. 14 1169-1176
45. Gorre M E, Ellwood-Yen K, Chiosis G, Rosen N and Sawyers C L 2002 BCR-ABL point mutants isolated from patients with STI571-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90; Blood 100 3041-3044
46. Gradin K, McGuire J, Wenger R H, Kvietikova I, fhitelaw M L, Toftgard R, Tora L, Gassmann M and Poellinger L 1996 Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor; Mol. Cell Biol. 16 5221-5231
47. Grbovic O M, Basso A, Sawai A, Ye Q, Friedlander P, Solit D and Rosen N 2006 V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors; Proc. Natl. Acad. Sci. USA 103 57-62
48. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D and Ross D 2005 Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition; Cancer Res. 65 10006-10015
49. Hahn W C and Weinberg R A 2002 Modelling the molecular circuitry of cancer; Nat. Rev. Cancer 2 331-341
50. Hanahan D and Weinberg R A 2000 The hallmarks of cancer; Cell 100 57-70
51. Harris A L 2002 Hypoxia- a key regulatory factor in tumor growth; Nat. Rev. Cancer 2 38-47
52. Hay D G, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith D L, Woodman B and Bates G P 2004 Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach; Hum. Mol. Genet. 13 1389-1405
53. He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino R M, Gewirth D T and Chiosis G 2006 Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90; J. Med. Chem. 49 381-390
54. Hershko A and Ciechanover A 1998 The ubiquitin system; Annu. Rev. Biochem. 67 425-479
55. Hu B R, Martone M E, Jones Y Z and Liu C L 2000 Protein aggregation after transient cerebral ischemia; J. Neurosci. 20 3191-3199
56. Hur E, Kim H H, Choi S M, Kim J H, Yim S, Kwon H J, Choi Y, Kim, D K, Lee M O and Park H 2002 Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol; Mol. Pharmacol. 62 975-982
57. Ichihara M, Murakumo Y and Takahashi M 2004 RET and neuroendocrine tumors; Cancer Lett. 204 197-211
58. Isaacs J S 2005 Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?; Expert. Opin. Investig. Drugs 14 569-589
59. Isaacs J S, Jung Y J, Mimnaugh E G, Martinez A, Cuttitta F and Neckers L M 2002 Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway; J. Biol. Chem. 277 29936-29944
60. Isaacs J S, Xu W and Neckers L 2003 Heat shock protein 90 as a molecular target for cancer therapeutics; Cancer Cell 3 213-217
61. Jhiang S M 2000 The RET proto-oncogene in human cancers; Oncogene 19 5590-5597
62. Kakizuka A 1998 Protein precipitation: a common etiology in neurodegenerative disorders?; Trends Genet. 14 396-402
63. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm M F, Fritz L C and Burrows F J 2003 A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors; Nature (London) 425 407-410
64. Kelland L R, Sharp S Y, Rogers P M, Myers T G and Workman P 1999 DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90; J. Natl. Cancer Inst. 91 1940-1949
65. Kim H R, Kang H S and Kim H D 1999 Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells; IUBMB Life 48 429-433
66. Kitano H 2003 Cancer robustness: tumour tactics; Nature (London) 426 125
67. Kruger R 2004 Genes in familial parkinsonism and their role in sporadic Parkinson's disease; J. Neurol. (Suppl. 6) 251 VI/2-6
68. L'Allemain G 2002 [Update on . . . the proteasome inhibitor PS341]; Bull. Cancer 89 29-30
69. La Rosee P, O'Dwyer M E and Druker B J 2002 Insights from preclinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective; Leukemia 16 1213-1219
70. Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies, P and Chiosis G 2005 Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90; J. Med. Chem. 48 2892-2905
71. Lu A, Ran R, Parmentier-Batteur S, Nee A and Sharp F R 2002 Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia; J. Neurochem. 81 355-364
72. Mabjeesh N J, Post D E, Willard M T, Kaur B, Van Meir E G, Simons J W and Zhong H 2002 Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteasome pathway in prostate cancer cells; Cancer Res. 62 2478-2482
73. Machida H, Matsumoto Y, Shirai M and Kubota N 2003 Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation; Int. J. Radiat. Biol. 79 973-980
74. Maulik G, Kijima T, Ma P C, Ghosh S K, Lin J, Shapiro G I, Schaefer E, Tibaldi E, Johnson B E and Salgia R 2002 Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer; Clin. Cancer Res. 8 620-627
75. Maxwell P H, Wiesener M S, Chang G -W, Clifford S C, Vaux E C, Cockman M E, Wykoff C C, Pugh C W, Maher E R and Ratcliffe P J 1999 The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis; Nature (London) 399 271-275
76. Mimnaugh E G, Chavany C and Neckers L 1996 Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin; J. Biol. Chem. 271 22796-22801
77. Mimnaugh E G, Xu W, Vos M, Yuan X, Isaacs J S, Bisht K S, Gius D and Neckers L 2004 Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity; Mol. Cancer Ther. 3 551-566
78. Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H and Naoe T 2002 Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors; Leukemia 16 1535-1540
79. Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann T A, Treon S P, Munshi N C, Richardson P G, Hideshima T and Anderson K C 2002 Molecular sequelae of proteasome inhibition in human multiple myeloma cells; Proc. Natl. Acad. Sci. USA 99 14374-14379
80. Naoe T, Kiyoe H, Yamamoto Y, Minami Y, Yamamoto K, Ueda R and Saito H 2001 FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy; Cancer Chemother. Pharmacol. 48 S27-S30
81. Nardai G, Vegh E M, Prohaszka Z and Csermely P 2006 Chaperone-related immune dysfunction: an emergent property of distorted chaperone networks; Trends Immunol. 27 74-79
82. Neckers L 2002 Hsp90 inhibitors as novel cancer chemotherapeutic agents; Trends Mol. Med. 8 S55-S61
83. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette P K, Loughran T, Tepperberg J, Jove R and Bhalla K 2002 Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin; Cancer Res. 62 5761-5769
84. Ouyang Y B and Hu B R 2001 Protein ubiquitination in rat brain following hypoglycemic coma; Neurosci. Lett. 298 159-162
85. Page J, Heath J, Fulton R et al 1997 Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats; Proc. Am. Assoc. Cancer Res. 38 abstract 2067
86. Paine-Murrieta G, Cook P, Taylor C W and Whitesell L 1999 The anti-tumor activity of 17-allylaminogeldanamycin is associated with modulation of target protien levels in vivo; Proc. Am. Assoc. Cancer Res. 40 abstract 119
87. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S and Comoglio P M 2003 Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene; Cancer Cell 3 347-361
88. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone M G, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich D I, Colombo G and Altieri D C 2005 Rational design of shepherdin, a novel anticancer agent; Cancer Cell 7 457-468
89. Polymeropoulos M H, Lavedan C, Leroy E, Ide S E, Dehejia A, Dutra A, Pike B and Root H 1997 Mutation in the alpha-synuclein gene identified in families with Parkinson's disease; Science 276 2045-2047
90. Prodromou C and Pearl L H 2003 Structure and functional relationships of Hsp90; Curr. Cancer Drug Targets 3 301-323
91. Queitsch C, Sangster T A and Lindquist S 2002 Hsp90 as a capacitor of phenotypic variation; Nature (London) 417 618-624
92. Rajagopalan H, Bardelli A, Lengauer C, Kinzler K W, Vogelstein B and Velculescu V E 2002 Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status; Nature (London) 418 934
93. Rutherford S L and Lindquist S 1998 Hsp90 as a capacitor for morphological evolution; Nature (London) 396 336-342
94. Santoro M, Melillo R M, Carlomagno F, Fusco A and Vecchio G 2002 Molecular mechanisms of RET activation in human cancer; Ann. N. Y. Acad. Sci. 963 116-121
95. Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C B, Ottmann O G, Schiffer C A, Talpaz M et al 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study; Blood 99 3530-3539
96. Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N and Hartl F U 1996 Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90; Proc. Natl. Acad. Sci. USA 93 14536-14541
97. Schnur R C, Corman M L, Gallaschun R J, Cooper B A, Dee M F, Doty J L, Muzzi M L, DiOrio C I, Barbacci E G, Miller P E et al 1995 erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships; J. Med. Chem. 38 3813-3820
98. Schulte T W and Neckers L M 1998 The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin; Cancer Chemother. Pharmacol. 42 273-279
99. Seizinger B R, Rouleau G A, Ozelius L J, Lane A H, Farmer G E, Lamiell J M, Haines J, Yuen J W, Collins D, Majoor-Krakauer D et al 1988 Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma; Nature (London) 332 268-269
100. Shah N P, Nicoll J M, Nagar B, Gorre M E, Paquette R L, Kuriyan J and Sawyers C L 2002 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia; Cancer Cell 2 117-125
101. Shimamura T, Lowell A M, Engelman J A and Shapiro G I 2005 Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins; Cancer Res. 65 6401-6408
102. Shiotsu Y, Neckers L M, Wortman I, An W G, Schulte T W, Soga S, Murakata C, Tamaoki T and Akinaga S 2000 Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex; Blood 96 2284-2291
103. Siligardi G, Hu B, Panaretou B, Piper P W, Pearl L H and Prodromou C 2004 Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle; J. Biol. Chem. 279 51989-51998
104. Solit D, Zheng F, Drobnjak M, Munster P, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus D, Scher H and Rosen N 2002 17-allylamino-17- demthoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts; Clin. Cancer Res. 986-993
105. Sreedhar A S, Soti C and Csermely P 2004 Inhibition of Hsp90: a new strategy for inhibiting protein kinases; Biochim. Biophys. Acta 1697 233-242
106. Stoler D L, Chen N, Basik M, Kahlenberg M S, Rodriguez-Bigas M A, Petrelli N J and Anderson G R 1999 The onset and extent of genomic instability in sporadic colorectal tumor progression; Proc. Natl. Acad. Sci. USA 96 15121-15126
107. Supko J G, Hickman R L, Grever M R and Malspeis L 1995 Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent; Cancer Chemother. Pharmacol. 36 305-315
108. Tacchini L, Dansi P, Matteucci E and Desiderio M A 2001 Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells; Carcinogenesis 22 1363-1371
109. Taylor J P, Hardy J and Fischbeck K H 2002 Toxic proteins in neurodegenerative disease; Science 296 1991-1995
110. Tofaris G K and Spillantini M G 2005 Alpha-synuclein dysfunction in Lewy body diseases; Mov. Disord. (Suppl 12) 20 S37-S44
111. Vanaja D K, Mitchell S H, Toft D O and Young C Y F 2002 Effect of geldanamycin on androgen receptor function and stability; Cell Stress Chaperones 7 55-64
112. Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P and Chiosis G 2004 Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90; Chem. Biol. 11 787-797
113. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H and Wanker E E 2001 Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation; Mol. Biol. Cell 12 1393-1407
114. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M and Sobue G 2005 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration; Nat. Med. 11 1088-1095
115. Wegele H, Muller L and Buchner J 2004 Hsp70 and Hsp90-a relay team for protein folding; Rev. Physiol. Biochem. Pharmacol. 151 1-44
116. Workman P 2004 Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone; Cancer Lett. 206 149-157
117. Xu L, Eiseman, J L, Egorin, M J and D'Argenio, D Z 2003 Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice; J. Pharmacokinet. Pharmacodyn. 30 185-219
118. Yu X, Guo Z S, Marcu M G, Neckers L, Nguyen D M, Chen G A and Schrump D S 2002 Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228; J. Natl. Cancer Inst. 94 504-513
119. Zagzag D, Nomura M, Friedlander D R, Blanco C, Gagner J P, Nomura N and Newcomb E W 2003 Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion; J. Cell Physiol. 196 394-402
120. Zhang H and Burrows F 2004 Targeting multiple signal transduction pathways through inhibition of Hsp90; J. Mol. Med. 82 488-499
121. Zhao R, Davey M, Hsu Y C, Kaplanek P, Tong A, Parsons A B, Krogan N, Cagney G, Mai D, Greenblatt J, Boone C, Emili A and Houry W A 2005 Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone; Cell 120 715-727
122. Zoghbi H Y and Orr H T 2000 Glutamine repeats and neurodegeneration; Annu. Rev. Neurosci. 23 217-247